Clinical Performance Evaluation of T-TAS 01 PL Chip

Normal Controls: Inclusion Criteria * Males and females age 21 years or older. * Able and willing to provide written informed consent. Exclusion Criteria * Abnormal results from assays used to establish clinical truth (retrospective exclusion). * Hospitalization or doctor's visits within prior 30 days, except for routine checkup/physical examination. * Use of antiplatelet therapy within the past 14 days, e.g. aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol. * Use of anticoagulant drugs within the past 14 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban. * Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) such as celecoxib, rofecoxib, etc. within the past 14 days. * History of anemia. * Known thrombocytopenia (platelet count \< 100,000/μL). * Significant renal dysfunction or dialysis. * History of platelet disorders e.g. von Willebrand factor deficiency, Glanzmann's thrombasthenia or Bernard-Soulier syndrome. * History of hemophilia or bleeding disorders. * History of bleeding, with Bleeding Score ≥ 5 (Tosetto J Thromb Haemost 2006). See Appendix A. Scores will be assigned based on health history according to the following categories: * Epistaxis * Cutaneous bleeding * Bleeding from minor wounds * Bleeding from oral cavity * Gastrointestinal bleeding * Bleeding from tooth extraction * Surgical bleeding * Menorrhagia * Post-partum hemorrhage * Muscle hematoma * Hemarthrosis * Central nervous system bleeding * Females who are in the last trimester of pregnancy, or are breastfeeding. * Known active gastrointestinal disease including peptic ulcers, gastro-esophageal reflux disease (GERD), and hyperacidity. * Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis. * Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals. Antiplatelet Therapy Subjects: Inclusion Criteria * Males and females age 21 years or older. * Continuous daily ingestion of one of the following antiplatelet therapy regimens: * 81 mg or higher aspirin * 81 mg or higher aspirin plus 75 mg daily clopidogrel * 81 mg or higher aspirin plus 10 mg daily prasugrel * 81 mg aspirin plus 180 mg daily ticagrelor * Able and willing to provide written informed consent. Exclusion Criteria * Use of antiplatelet therapy besides aspirin (e.g. clopidogrel, prasugrel, ticagrelor, cilostazol, abciximab, eptifibatide) within the past 14 days. * Use of anticoagulant drugs within the past 14 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban. * Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) such as celecoxib, rofecoxib, etc. within the past 14 days. * Significant renal dysfunction or dialysis. * Known thrombocytopenia (platelet count \< 100,000/μL). * History of platelet disorders e.g. von Willebrand factor deficiency, Glanzmann thrombasthenia or Bernard-Soulier syndrome. * History of hemophilia or bleeding disorders. * Females who are in the last trimester of pregnancy, or are breastfeeding. * Known active gastrointestinal disease including peptic ulcers, gastro-esophageal reflux disease (GERD), and hyperacidity. * Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis. * Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals. vWD Subjects: Inclusion Criteria * Males and females age 21 years or older. * Prior diagnosis of von Willebrand disease type 1, 2A, 2B, 2M, or 3 * History of bleeding, with Bleeding Score ≥ 5, which is 99% specific for vWD (Tosetto J Thromb Haemost 2006). See Appendix A. Scores will be assigned based on health history according to the following categories: * Epistaxis * Cutaneous bleeding * Bleeding from minor wounds * Bleeding from oral cavity * Gastrointestinal bleeding * Bleeding from tooth extraction * Surgical bleeding * Menorrhagia * Post-partum hemorrhage * Muscle hematoma * Hemarthrosis * Central nervous system bleeding * Able and willing to provide written informed consent. Exclusion Criteria * Prior diagnosis of von Willebrand disease type 2N * Receiving desmopressin or vWF replacement therapy within the past 2 weeks. * Use of antiplatelet therapy within the past 14 days. * Use of anticoagulant drugs within the past 14 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban. * Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) such as celecoxib, rofecoxib, etc. within the past 14 days. * Significant renal dysfunction or dialysis. * Known thrombocytopenia (platelet count \< 100,000/μL). * Females who are in the last trimester of pregnancy, or are breastfeeding. * Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis. * Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals. Glanzmann's Thrombasthenia Subjects: Inclusion Criteria * Males and females age 21 years or older. * Prior diagnosis of Glanzmann's thrombasthenia * History of bleeding. * Able and willing to provide written informed consent. Exclusion Criteria * Use of antiplatelet therapy within the past 14 days. * Use of anticoagulant drugs within the past 14 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban. * Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) such as celecoxib, rofecoxib, etc. within the past 14 days. * Significant renal dysfunction or dialysis. * Known thrombocytopenia (platelet count \< 100,000/μL). * Females who are in the last trimester of pregnancy, or are breastfeeding. * Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis. * Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals.